APA (7th ed.) Citation

A, F., V, M., LL, R., F, L., G, F., D, M., . . . CA, D. (2011). Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Molecular medicine (Cambridge, Mass.), 17(5-6), 353. https://doi.org/10.2119/molmed.2011.00020

Chicago Style (17th ed.) Citation

A, Furlan, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, and Dinarello CA. "Pharmacokinetics, Safety and Inducible Cytokine Responses During a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (givinostat)." Molecular Medicine (Cambridge, Mass.) 17, no. 5-6 (2011): 353. https://doi.org/10.2119/molmed.2011.00020.

MLA (9th ed.) Citation

A, Furlan, et al. "Pharmacokinetics, Safety and Inducible Cytokine Responses During a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (givinostat)." Molecular Medicine (Cambridge, Mass.), vol. 17, no. 5-6, 2011, p. 353, https://doi.org/10.2119/molmed.2011.00020.